TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04068974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab (SHR-1210)
Description: Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
Study: NCT01345994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: acupuncture stimulation with electricity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: acupuncture stimulation with electricity
Study: NCT02384850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
Study: NCT04463290

Intervention type: OTHER
Intervention: No intervention, Patients selection based on clinical symptoms and radiological imaging
Description: No intervention

Intervention type: OTHER
Intervention: No intervention, Patients selection based on clinical symptoms and radiological imaging
Description: No intervention
Study: NCT03642353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan
Description: Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan
Description: Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
Study: NCT04013113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haemoperfusion
Description: Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
Study: NCT00870818

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of T-cell subsets
Description: CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Analysis of T-cell subsets
Description: CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of T-cell subsets
Description: CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
Study: NCT01938690

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: 8 sessions of TMS followed by task specific training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: 8 sessions of TMS followed by task specific training
Study: NCT01333852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin up to 2500mg/d
Description: metformin up to 2500mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel 175mg/m² q21d
Description: paclitaxel 175mg/m² q21d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel 175mg/m² q21d
Description: paclitaxel 175mg/m² q21d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02863939

Intervention type: DEVICE
Group type: OTHER
Intervention: Single photon emission computed tomography myocardial perfusion imaging
Description: a novel cadmium-zinc-telluride (CZT) SPECT camera

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Study: NCT04699552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 120W Lumenis Holmium:YAG laser 20J
Description: 120W Lumenis Holmium:YAG laser 20J

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 120W Lumenis Holmium:YAG laser 40 J
Description: 120W Lumenis Holmium:YAG laser 40J
Study: NCT01334918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidetector Computed Tomography
Description: Procedure/Surgery
Study: NCT04699552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 120W Lumenis Holmium:YAG laser 60 J
Description: 120W Lumenis Holmium:YAG laser 60J
Study: NCT01732185

Intervention type: GENETIC
Group type: OTHER
Intervention: Patient
Description: Blood and histological samples will be done at day of the inclusion.
Study: NCT02471001

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Two additional blood samples will be taken from in-situ catheters during heart surgery.
Study: NCT00280241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is usually administered by IV infusion over 30 minutes or longer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
Study: NCT02769351

Intervention type: DEVICE
Intervention: periph. minimal invasive ultrafiltration
Description: ultrafiltration via a peripheral single-needle
Study: NCT02489006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: Chosen by the study doctor, per standard of care.
Study: NCT04013113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Fresh frozen plasma will be used as replacement fluid.TPE treatment shall be given on first day and continued on an a dailybasis/alternate day till the desired clinical or biochemical response is achieved.~The procedures of TPE and hemoperfusion will be stopped if any major side effects occur (described below), the patient expires or the patient is transplanted within 30 days (whichever is earlier).
Study: NCT04561921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
Study: NCT03184220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~* Suboccipital induction~* Posterior elongation of the cervical fascia in Supine position~* Assisted cervical fascia~* Myofascial induction of sternocleidomastoid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
Study: NCT04561921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine-Levonordefrin Hydrochloride
Description: patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
Study: NCT04357990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viruxal Oral and Nasal Spray
Description: Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be a similar spray containing saline only.
Study: NCT01475253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Releasing Intravesical System - LiRIS®
Description: Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LiRIS Placebo
Description: LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Cystoscopy Procedure
Description: Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
Study: NCT01129453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine
Description: CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10\^6, 10\^7, 10\^8, or 10\^9 CFU per mL. Route: oral.
Study: NCT03763903

Intervention type: OTHER
Group type: OTHER
Intervention: 3D training
Description: Skills (FLS tasks) training using 3D visualization

Intervention type: OTHER
Group type: OTHER
Intervention: 2D training
Description: Skills (FLS tasks) training using 2D visualization
Study: NCT01129453

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
Study: NCT02611063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: 100mg qd, 150mg qd, or 100mg bid
Study: NCT01088438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contextualization workshop
Description: A four-hour course on contextualization.
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg
Study: NCT00378950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach to Goal (TTG)
Description: The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Educational Intervention (BEI)
Description: The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
Study: NCT01154959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Description: Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Description: Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Description: Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Description: Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Description: Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg
Study: NCT00041938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 325 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: INR 2.5-3.0; target INR 2.75
Study: NCT06235424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Del Nido Cardioplegia Solution
Description: The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4\*C.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTK solution
Description: The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4\*C
Study: NCT04368312

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, just of questionnaire including validated tests
Study: NCT03635151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Assessment and Skill-Building Kit (TASK III) Group
Description: The TASK III group will receive a TASK III Resource Guide that we developed and 8 weekly calls from a nurse. The nurse will call again a month later. The TASK III nurse will help you assess your needs and concerns, build your skills as a caregiver, and refer you to community resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Support and Referral (ISR) Group
Description: The ISR group will receive an American Heart Association brochure and 8 weekly calls from a nurse. The nurse will call again a month later. The ISR nurse will provide information, support, and referral to community resources.
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214 Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg
Study: NCT04478942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Oral Product
Description: Misoprostol will be dosed using the preexisting UnityPoint Health-Meriter Protocol for oral misoprostol administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Oxytocin
Description: Intravenous oxytocin administration will also follow standard, UnityPoint Health-Meriter Protocol.
Study: NCT02045810

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline